Drug intelligence / Profile preview

flufirvitide

Development stage: Phase 2
Lead developer: Tulane School of Medicine
Modality: Peptides, Small Molecules
Administration: Intranasal

Overview

Flufirvitide (also known as Flufirvitide-3) is a synthetic peptide antiviral drug candidate developed for the treatment of influenza. It acts as an inhibitor of hemagglutinin-neuraminidase (HN), a key glycoprotein on the surface of influenza viruses that is essential for viral entry and release from host cells. By inhibiting HN, flufirvitide disrupts the virus's ability to infect new cells and propagate within the respiratory tract. The drug has been investigated primarily in nasal spray formulations and has reached Phase 2 clinical development for human influenza[5][2].

Brand names: FF-3FF3FF 3
Other names: Flufirvitide-3Flufirvitide3Flufirvitide 3

Targets

HN (Hemagglutinin-neuraminidase protein)

Beyond the preview

Go deeper on flufirvitide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on flufirvitide.

Explore the full profile